ICPT - Breaking Down The NASH Fibrosis Market - Intercept Genfit Primed For Potential Market Dominance
Over the past year, interest has heated up in the biotech industry about NASH, with analysts estimating market size in 2025 anywhere between $20-35 billion. Positive Phase 2 data readouts for Madrigal (NASDAQ: MDGL) and Galmed (NASDAQ: GLMD) caused both stocks to more than double overnight in late May and early June, respectively. With Phase 3 data readouts due next year for Intercept (NASDAQ: ICPT), Genfit (OTCPK: GNFTF), and possibly Allergan's (NASDAQ: AGN) NASH candidates, the race to approval is nearly complete - one of these drugs will likely be